Oric Pharmaceuticals, Inc. · NASDAQ:ORIC

Oric Pharmaceuticals — FY2021 Earnings Presentation

15 slides from Oric Pharmaceuticals's earnings presentation, Mar 21, 2022

  1. Slide 1: Fourth Quarter and Full Year 2021 Financial Results and Operational Update

    Fourth Quarter and Full Year 2021 Financial Results and Operational Update March 21, 2022 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us”

  3. Slide 3: Agenda and Participants

    Fourth Quarter and Full Year 2021 Financial Results and Operational Update Executive Summary Update on ORIC-101 + Enzalutamide Update on ORIC-101 + Nab-paclitaxel Pipeline Update and Summary Agenda Participants Jacob Chacko, Chief Executive Officer Pratik Multani, Chief Medical Officer Dominic Pisci

  4. Slide 4: Executive Summary

    Executive Summary Recently completed interim analyses from the two Phase 1b combination studies of ORIC-101 + nab-paclitaxel in solid tumors and ORIC-101 + enzalutamide in mCRPC We believe that further development of ORIC-101 should be discontinued due to a lack of sufficient efficacy signal to meet

  5. Slide 5: Update on ORIC-101 + Enzalutamide

    Update on ORIC-101 + Enzalutamide

  6. Slide 6: Phase 1b Study of ORIC-101 + Enzalutamide in Metastatic Prostate Cancer: Interim Analysis

    Phase 1b Study of ORIC-101 + Enzalutamide in Metastatic Prostate Cancer: Interim Analysis Key Eligibility Metastatic prostate cancer progressing on enzalutamide ECOG 0-1 Independent of baseline GR status Screening / Enrollment RP2D Determined Screening / Enrollment RP2D: 240 mg ORIC-101 QD + 160 mg

  7. Slide 7: Phase 1b Interim Analysis Results Summary

    Phase 1b Interim Analysis Results Summary Safety: The combination regimen was generally well tolerated at the RP2D Translational: PK data confirmed ORIC-101 achieved exposures necessary for GR target coverage PD data demonstrated downregulation of GR target genes, confirming target engagement Majori

  8. Slide 8: Update on ORIC-101 + Nab-paclitaxel

    Update on ORIC-101 + Nab-paclitaxel

  9. Slide 9: Phase 1b Study of ORIC-101 + Nab-Paclitaxel in Advanced Solid Tumors: Interim Analysis

    Phase 1b Study of ORIC-101 + Nab-Paclitaxel in Advanced Solid Tumors: Interim Analysis Note: ClinicalTrials.gov identifier: NCT03928314. Key Eligibility Advanced or metastatic solid tumors Received prior standard therapies ECOG 0-1 Independent of baseline GR status Dose Expansion (Part II) Dose Esca

  10. Slide 10: Phase 1b Interim Analysis Results Summary

    Phase 1b Interim Analysis Results Summary Safety: The combination regimen was generally well tolerated at the RP2D Translational: PK data confirmed ORIC-101 achieved exposures necessary for GR target coverage PD data demonstrated downregulation of GR target genes, confirming target engagement High G

  11. Slide 11: Potential Reasons for Lack of Clinical Benefit

    Potential Reasons for Lack of Clinical Benefit Suboptimal exposure of ORIC-101 Unlikely: PK data demonstrate exposures sufficient for target coverage Insufficient target engagement Unlikely: Extensive PD data demonstrate target engagement with inhibition of GR signaling genes Tumor heterogeneity Pos

  12. Slide 12: Pipeline Update and Summary

    Pipeline Update and Summary

  13. Slide 13: Broad Pipeline Targeting Multiple Resistance Mechanisms

    Broad Pipeline Targeting Multiple Resistance Mechanisms Program Lead Identification Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 Indication Multiple Myeloma PRODUCT CANDIDATES DISCOVERY RESEARCH PROGRAMS Multiple programs targeting resistance mechanisms ORIC-533 CD73 inhibitor Breast cance

  14. Slide 14: Financial Highlights

    Financial Highlights As a result of the discontinuation of ORIC-101, cash runway extended from 1H 2024 to 2H 2024 4Q 2021 and 2021 Financial Results Represents cash, cash equivalents and investments as of December 31, 2021.

  15. Slide 15: ORIC Pharmaceuticals: Dedicated to Overcoming Resistance In Cancer

    ORIC Pharmaceuticals: Dedicated to Overcoming Resistance In Cancer Broad Pipeline of Potential First-in-Class and Best-in-Class Programs Dual Engines for Pipeline Expansion Strong Financial Position and Multiple Upcoming Milestones Experienced Management Team Three ongoing potential best-in-class Ph

ORIC Pharmaceuticals — FY2021 Earnings Presentation on 6ix